"Many times obesity treatment is framed as a limited duration intervention that once people get to a weight goal or percentage of weight reduction, that then treatment can be discontinued," Almandoz says
The evidence balance on compounded GLP-1 safety The National Center for Complementary and Integrative Health (NCCIH), the FDA, and multiple medical societies - including the American Diabetes Association - have published guidance noting that compounded GLP-1 preparations carry additional safety uncertainty compared to FDA-approved finished products
Semaglutide Semaglutide, sold as Wegovy and Ozempic, is a GLP-1 receptor agonist widely used for obesity and metabolic health
Contact your GP, healthcare provider, or if you need urgent advice NHS 111 if you experience: A persistent resting heart rate above 100 bpm (resting tachycardia) Palpitations a sensation of a racing, fluttering, or pounding heartbeat Dizziness, light-headedness, or near-fainting episodes Chest discomfort or tightness, particularly if associated with exertion Shortness of breath that is new or worsening Fatigue that is disproportionate to your level of activity Seek emergency medical attention (call 999 or go to A&E) if you experience: Chest pain radiating to the arm, jaw, or back Sudden severe breathlessness Loss of consciousness or collapse A very rapid or irregular heartbeat that does not settle within a few minutes Some symptoms, such as mild palpitations or a sensation of a faster heartbeat, may be transient and occur particularly after dose escalation
Your card gets charged
Discount applied at checkout Free shipping on every subscription order 24/7 clinician access, 100% online Easy & reliable refills delivered to your door Limited time offer with your subscription